Sirona Biochem Announces Close of Private Placement
April 04 2024 - 8:24PM
Vancouver, British Columbia – April 4, 2024 –
Sirona Biochem Corp. (TSX-V: SBM) (Frankfurt: ZSB)
(“
Sirona”) has closed its private placement
(Private Placement”) for gross proceeds of $132,500 CAD. The
Private Placement consists of 1,325,000 units, (the “Units”) at a
price of $0.10 per Unit. Each Unit consists of one common share and
one transferable share purchase warrant, each whole warrant
exercisable into one additional common share of the Company for a
period of 2 years from the date of issue at a price of $0.15 per
Share in year one and $0.25 per Share in year two. All securities
issued under the Private Placement are subject to statutory hold
periods expiring on August 4, 2024.
Proceeds will be used for general working
capital purposes.
No insiders participated in the Private
Placement.
No finders’ fees were paid from the Private
Placement.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug
discovery company with a proprietary platform technology. Sirona
specializes in stabilizing carbohydrate molecules with the goal of
improving efficacy and safety. New compounds are patented for
maximum revenue potential.
Sirona’s compounds are licensed to leading
companies around the world in return for licensing fees, milestone
fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is
located in France and is the recipient of multiple French national
scientific awards and European Union and French government grants.
For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
For more information regarding this press
release, please contact:
Christopher Hopton, CFO,604-641-4466Email:
Info@sironabiochem.com
Sirona Biochem cautions you that statements
included in this press release that are not a description of
historical facts may be forward-looking statements. Forward-looking
statements are only predictions based upon current expectations and
involve known and unknown risks and uncertainties. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of release of the
relevant information, unless explicitly stated otherwise.
Actual results, performance or achievement could differ materially
from those expressed in, or implied by, Sirona Biochem’s
forward-looking statements due to the risks and uncertainties
inherent in Sirona Biochem’s business including, without
limitation, statements about: the progress and timing of its
clinical trials; difficulties or delays in development, testing,
obtaining regulatory approval, producing and marketing its
products; unexpected adverse side effects or inadequate therapeutic
efficacy of its products that could delay or prevent product
development or commercialization; the scope and validity of patent
protection for its products; competition from other pharmaceutical
or biotechnology companies; and its ability to obtain additional
financing to support its operations. Sirona Biochem does not assume
any obligation to update any forward-looking statements except as
required by law.
Sirona Biochem (TG:ZSB)
Historical Stock Chart
From Nov 2024 to Dec 2024
Sirona Biochem (TG:ZSB)
Historical Stock Chart
From Dec 2023 to Dec 2024